Chemistry: analytical and immunological testing – Peptide – protein or amino acid
Reexamination Certificate
2007-07-03
2007-07-03
Warden, Jill (Department: 1743)
Chemistry: analytical and immunological testing
Peptide, protein or amino acid
C436S173000, C702S022000, C702S023000, C702S027000
Reexamination Certificate
active
11169169
ABSTRACT:
A method for interpreting data that is produced after a group of amino acids and acylcarnitines are derivatized from blood spots taken from newborn babies and scanned by a tandem mass spectrometer. Concentration levels of each metabolite, which are directly proportional to the butyl ester fragment after derivatization, are compared to threshold flags for determining a significance of any deviation of the metabolite relative to the flag threshold. The threshold flags are diagnostic limits to the data retrieved from each blood spot. The data includes metabolite concentrations and molar ratios of metabolites with other metabolites. Samples are labeled normal for a disease if the concentration of any of the metabolite concentrations or molar ratio concentration do not deviate from the flag threshold, but, in contrast, the sample must be further evaluated if a value is elevated or deficient to some degree. Thus, as each metabolite fragments at a different mass to charge value (m/z), corresponding data is compared to the respective flag thresholds for determining a next course of action that must be taken to ultimately assist a physician in the diagnosis of a genetic disorder resulting from an elevation or deficiency of the metabolite particular for that disorder.
REFERENCES:
patent: 4224031 (1980-09-01), Mee et al.
patent: 5072115 (1991-12-01), Zhou
patent: 5206508 (1993-04-01), Alderdice et al.
patent: 5251126 (1993-10-01), Kahn et al.
patent: 5252489 (1993-10-01), Macri
patent: 5316917 (1994-05-01), Roe
patent: 5352891 (1994-10-01), Monnig et al.
patent: 5365426 (1994-11-01), Siegel et al.
patent: 5453613 (1995-09-01), Gray et al.
patent: 5538897 (1996-07-01), Yates et al.
patent: 5545895 (1996-08-01), Wright et al.
patent: 5629210 (1997-05-01), Hercules et al.
patent: 5878746 (1999-03-01), Lemelson et al.
patent: 6258605 (2001-07-01), Chace
patent: 6335369 (2002-01-01), Cavazza
patent: 6429230 (2002-08-01), Cavazza
patent: 6455321 (2002-09-01), Chace
patent: 6653349 (2003-11-01), Cavazza
patent: 6696492 (2004-02-01), Cavazza
patent: 6696493 (2004-02-01), Cavazza
Rashed, et al., “Screening blood spots for inborn errors of metabolism by electrospray tandem mass spectrometry with a microplate batch process and a computer algorithm for automated flagging of abnormal profiles,” Clinical Chem., vol. 43:7, pp. 1129-1141, (1997).
Nada, M., et al., “Investigation of Beta-Oxidation Intermediates in Normal MCAD-Deficient Human Fibroblasts Using Tandem Mass Spectrometry,” Biochemical and Molecular Med., vol. 54, No. 1, pp. 59-66 (1995).
Chace, D., “Used of phenylalnine-to-tyrosine ratio determined by tandem mass spec . . .,” Clin. Chem., vol. 44:12 (1998).
Abdenur, J., et al., Diagnosis of Isovaleric Acidaemia by Tandem Mass Spectrometry: False Positive Result due to Pivaloyl Carnitine in a Newborn Screening Programme; J. Inher. Metab. Dis., vol. 21, pp. 624-630 (1998).
Abdenur, J., et al., “MCAD Deficiency: Acylcarnitines (AC) by Tandem Mass Spectrometry (MS-MS) are Useful to Monitor Dietary Treatment,” Adv. Exp. Med. Biol., vol. 466, pp. 353-363 (1999).
Albers, S., et al., “Detection of Neonatal Carnitine Palmitoyltransferase II Deficiency by Expanded Newborn Screening with Tandem Mass Spectrometry,” Pediatrics 2001; 107:E103.
Barns, R., et al., “Carnitine in Dried Blood Spots: A Method Suitable for Neonatal Screening,” Clin. Chim. Acta, vol. 197, pp. 27-33 (1991).
Chace, D., et al, “Errors Caused by the Use of D,L-octanoly Carnitine for Blood-Spot Calibrators,” Clin. Chem. vol. 47, pp. 758-760 (2001).
Clayton, P., et al, “Screening for Medium Chain Acyl-coA Dehydrogenase Deficiency using Electrospray Ionisation Tandem Mass Spectrometry,” Arch. Dis. Child, vol. 79, pp. 109-115 (1998).
Gaskell, S., et al., “Differentation of Isomeric Acylcarnitines using Tandem Mass Spectrometry,” Anal. Chem., vol. 58, pp. 2801-2805 (1986).
Gempel, K., et al. “Adult Carnitine Palmitoyltranferase II Deficiency: Detection of Characteristic Carnitine Esters in Serum by Tandem Mass Spectrometry,” J. Inherit. Metab. Dis., vol. 22, pp. 941-942 (1999).
Johnson, A., et al., “The Use of Automated Electrospray Ionization Tandem MS for the Diagnosis of Inborn Errors of Metabolism from Dried Blood Spots,” Biochem. Soc. Trans., vol. 24, pp. 932-938 (1996).
Johnson, D., “Inaccurate Measure of Free Carnitine by the Electrospray Tandem Mass Spectrometry Screening Methods for Blood Spots,” J. Inher. Metab. Dis., vol. 22, pp. 201-202 (1999).
Kodo, N., et al., “Quantitative Assay of Free and Total Carnitine using Tandem Mass Spectrometry,” Clin. Chim. Acta, vol. 186, pp. 383-390 (1989).
Liberato, D., et al., “Analysis of Acylcamitines in Human Metabolic Disease by Thermospray Liquid Chromatography/Mass Spectrometry,” Burlingame A.A. Castagnoli N., editors, Mass Spectrometry in the Health and Life Sciences, Amsterdam, NL; Elsevier Science Publishers, pp. 333-348 (1958).
Millington, D., et al., “Application of Fast Atom Bombardment with Tandem Mass Spectrometry and Liquid Chromatography/Mass Spectrometry to the Analysis of Acylcamitines in Human Urine, Blood and Tissue,” Anal. Biochem., vol. 180, pp. 331-339 (1989).
Millington, D., et al., “Tandem Mass Spectrometry: A New Method for Acylcamitines Profiling with Potential for Neonatal Screening for Inborn Errors of Metabolism,” J. Inher. Dis., vol. 13, pp. 321-324 (1990).
Stevens, R., et al., “Assay for Free and Total Carnitine in Human Plasma Using Tandem Mass Spectrometry,” Clin. Chem., vol. 46, pp. 727-729 (2000).
Vreken, P., et al., “Quantitative Plasma AcylCarnitine Analysis Using Electrospray Tandem Mass Spectrometry for the Diagnosis of Organic Acidaemias and Fatty Acid Oxidation Defects,” J. Inher. Metab. Dis., vol. 22, pp. 302-306 (1999).
Willey, V., et al., “Newborn Screening with Tandem Mass Spectrometry; 12 Months' Experience in NSW Australia,” Acta Paediatr Suppl., vol. 88, pp. 48-51 (1999).
Yergey, A., et al., “Thermospray Liquid Chromatography/ Mass Spectrometry for the Analysis of L-Carnitine and its Short-Chain Acyl Derivatives,” Anal Biochem., vol. 139, pp. 278-283 (1984).
Savica, et al., “Plasma & Muscle Carnitine Levels in Haemodialysis Patients with Morphological-Ulstructural Examination of Muscle Samples,” Nephron, vol. 35, pp. 232-236 (1983).
Rodriguez-Segade, et al., “Camitine deficiency in haemodialysed patients,” Clinical Chimica Acta, vol. 59, pp. 249-256 (1986).
Rodriguez-Segade, et al., “Camitine concentrations in dialysed and undialysed patients with chronic renal insufficiency,” Ann. Clinical Biochemistry, vol. 23, pp. 671-675 (1986).
Millington, D., et al; Diagnosis of Metabolic Disease,Biological Mass Spectrometry: Present and Future, 1994; pp. 559-579.
Millington, D., et al; Carnitine and Acylcarnitines in Metabolic Disease Diagnosis and Management;Mass Spectrometry: Clinical and Biomedical Applications, vol. 1; pp. 299-318.
Millington, D., et al; The Analysis of Diagnostic Markers of Genetic Disorders in Human Blood and Urine using Tandem Mass Spectrometry with Liquid Secondary Ion Mass Spectrometry;International Journal of Mass Spectrometry and Ion Processes, 111; 1991; pp. 211-228.
Van Hove, J., et al; Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency: Diagnosis by Acylcarnitine Analysis in Blood;Am. J. Hum. Genet. S2; pp. 958-966.
Chace, D., et al; Rapid Diagnosis of Maple Syrup Urine Disease in Blood Spots from Newborns by Tandem Mass Spectrometry;Clinical Chemistry, vol. 41 (1); 1995; pp. 62-68.
Chace, D., et al; Rapid Diagnosis of Homocystinuria and Other Hypermethioninemias from Newborns' Blood Spots by Tandem Mass Spectrometry;Clinical Chemistry, vol. 42 (3); 1996; pp. 349-355.
Chace, D., et al; Rapid Diagnosis of Phenylketonuria by Quantitative Analysis for Phenylalanine and Tyrosine in Neonatal Blood Spots b
Choate Hall & Stewart LLP
Pediatrix Screening, Inc.
Warden Jill
LandOfFree
Method for interpreting tandem mass spectrometry data for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for interpreting tandem mass spectrometry data for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for interpreting tandem mass spectrometry data for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3738794